GT200100106A - Combinaciones de carboxialquileter - inhibidor de acat. - Google Patents

Combinaciones de carboxialquileter - inhibidor de acat.

Info

Publication number
GT200100106A
GT200100106A GT200100106A GT200100106A GT200100106A GT 200100106 A GT200100106 A GT 200100106A GT 200100106 A GT200100106 A GT 200100106A GT 200100106 A GT200100106 A GT 200100106A GT 200100106 A GT200100106 A GT 200100106A
Authority
GT
Guatemala
Prior art keywords
carboxialquileter
acat inhibitor
combinations
arteroscleroisis
aciltransferiaid
Prior art date
Application number
GT200100106A
Other languages
English (en)
Inventor
Bruce Jeffrey Auerbach
Donna Lee Zobel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200100106A publication Critical patent/GT200100106A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN CARBOXIALQUILETER QUE REDUCE TRIGLICERIDOS Y LDL Y ELEVA HDL Y UN INHIBIDOR DE ACAT O MEJOR CONOCIDO COMO ACILCOENZIMA A : COLESTEROL ACILTRANSFERASA, QUE MEJORA LA DISLIPIDEMIA EN MAMIFEROS, DICHA COMPOSICION ES UTIL PARA TRATAR LA DISPLIPIDEMIA Y SINDROMES ISQUEMICOS Y PARA PREVENIR O RETARDAR EL COMIENZO DE ATAQUES CARDIACOS, ADEMAS SIRVE PARA TRATAR LA HIPERCOLESTEROLEMIA Y LA ARTEROSCLEROISIS.
GT200100106A 2000-06-07 2001-06-05 Combinaciones de carboxialquileter - inhibidor de acat. GT200100106A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21005600P 2000-06-07 2000-06-07

Publications (1)

Publication Number Publication Date
GT200100106A true GT200100106A (es) 2002-05-20

Family

ID=22781424

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200100106A GT200100106A (es) 2000-06-07 2001-06-05 Combinaciones de carboxialquileter - inhibidor de acat.

Country Status (14)

Country Link
EP (1) EP1292363A2 (es)
JP (1) JP2003535125A (es)
AR (1) AR034255A1 (es)
AU (1) AU2001263003A1 (es)
BR (1) BR0111428A (es)
CA (1) CA2413906A1 (es)
GT (1) GT200100106A (es)
MX (1) MXPA02010762A (es)
PA (1) PA8518601A1 (es)
PE (1) PE20020265A1 (es)
SV (1) SV2002000466A (es)
TN (1) TNSN01085A1 (es)
UY (1) UY26752A1 (es)
WO (1) WO2001093845A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7387236B2 (en) 2001-10-09 2008-06-17 Delaware Capital Formation, Inc. Dispensing of currency

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038498A1 (en) * 1998-01-28 1999-08-05 Warner-Lambert Company Method for treating alzheimer's disease

Also Published As

Publication number Publication date
SV2002000466A (es) 2002-04-03
WO2001093845A2 (en) 2001-12-13
WO2001093845A3 (en) 2002-10-10
EP1292363A2 (en) 2003-03-19
AU2001263003A1 (en) 2001-12-17
MXPA02010762A (es) 2003-03-10
PE20020265A1 (es) 2002-04-19
AR034255A1 (es) 2004-02-18
CA2413906A1 (en) 2001-12-13
UY26752A1 (es) 2001-07-31
BR0111428A (pt) 2003-06-10
PA8518601A1 (es) 2002-07-30
JP2003535125A (ja) 2003-11-25
TNSN01085A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
UY26929A1 (es) Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis
GT200500137A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis.
PA8506101A1 (es) Uso de un compuesto acat para fabricar una composicion farmaceutica
GT200000158A (es) Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis.
GT200300053A (es) Compuestos que modulan la actividad de ppar
UY26883A1 (es) Combinación terapéutica
AR022023A1 (es) Combinaciones de inhibidores del transporte de acido ileo-biliar con derivados del acido fibrico para prescripciones cardiovasculares
GT200300054A (es) Compuestos que modulan la actividad de ppar
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
PA8513601A1 (es) Composiciones farmaceuticas de inhibidores de la glucogenofosforilasa
AR109263A2 (es) Composición que comprende moxidectina
GT200000077A (es) Sal mutua de amlodipino y atorvastatina
MX2008001597A (es) Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento.
PA8684501A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
BR0213181A (pt) Combinações de inibidor de cox-2
ECSP003707A (es) Diazepanes
PA8464601A1 (es) Combinaciones de estatina-eter carboxialquilico
AR054368A1 (es) Metodo para tratar hiperlipidemia
GT200100106A (es) Combinaciones de carboxialquileter - inhibidor de acat.
MA44513B1 (fr) Formulations injectables de fosnetupitant physiologiquement equilibrees
SV2004000109A (es) Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicamentos ref.lea 33846-sv
PA8469001A1 (es) Combinaciones de estatina-inhibidor de mmp.
DOP2001000150A (es) Agente hipertensivo y su uso
SV2002000639A (es) Alcanosulfonatos de fenoxifenilo ref. lea 34813-sv